
Fibrobiologics Inc (FBLG) Stock Forecast & Price Target
Fibrobiologics Inc (FBLG) Analyst Ratings
Bulls say
FibroBiologics Inc. is focusing on the development of innovative fibroblast-based therapies that demonstrate promising advancements in wound healing and chronic disease management, underscored by positive preclinical results. The company is committed to scaling manufacturing and improving operational efficiencies, signaling a pathway for reduced production costs and streamlined regulatory processes in the clinical and commercial realms. Furthermore, the firm is progressing in key preclinical studies and manufacturing preparations for multiple investigational therapies, which showcases its potential for broad therapeutic applicability and positions it favorably within a market characterized by significant unmet medical needs.
Bears say
FibroBiologics Inc. faces significant financial challenges, highlighted by a net loss of $5.8 million for the third quarter of 2025, along with an over 80% decline in stock value year-to-date, contrasting sharply with the broader Nasdaq Biotechnology Index's 20% increase. The company's escalating research and development costs, driven by CRO, cell manufacturing, and personnel expenses, have further contributed to deepening losses, despite some efforts to implement cost-efficiency measures. Additionally, the potential failure of developmental candidates to meet commercial revenue estimates, coupled with uncertainties regarding capital resource acquisition and program development timelines, poses substantial risks to the company’s financial stability and future prospects.
This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.
Fibrobiologics Inc (FBLG) Analyst Forecast & Price Prediction
Start investing in Fibrobiologics Inc (FBLG)
Order type
Buy in
Order amount
Est. shares
0 shares